Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer

• Published in: Chemico-biological interactions Vol. 396; p. 111055
• Main Authors: Tufail, Muhammad, Wan, Wen-Dong, Jiang, Canhua, Li, Ning
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01-06-2024
• Subjects: Cancer resistance; Cancer therapies; Mechanisms of resistance; PI3K inhibitors; PI3K/AKT/mTOR; Cancer resistance; PI3K/AKT/mTOR; PI3K inhibitors; Cancer therapies; Mechanisms of resistance; Cancer Therapies
• ISSN: 0009-2797; 1872-7786; 1872-7786
• DOI: 10.1016/j.cbi.2024.111055

This review comprehensively explores the challenge of drug resistance in cancer by focusing on the pivotal PI3K/AKT/mTOR pathway, elucidating its role in oncogenesis and resistance mechanisms across various cancer types. It meticulously examines the diverse mechanisms underlying resistance, including genetic mutations, feedback loops, and microenvironmental factors, while also discussing the associated resistance patterns. Evaluating current therapeutic strategies targeting this pathway, the article highlights the hurdles encountered in drug development and clinical trials. Innovative approaches to overcome resistance, such as combination therapies and precision medicine, are critically analyzed, alongside discussions on emerging therapies like immunotherapy and molecularly targeted agents. Overall, this comprehensive review not only sheds light on the complexities of resistance in cancer but also provides a roadmap for advancing cancer treatment.